Betta Pharmaceuticals Co., Ltd.

FDA approved ensartinib for ALK-positive NSCLC, a first-choice treatment for untreated patients with locally advanced or metastatic disease. Ensartinib, a second-generation ALK inhibitor, improves progression-free survival to 25.8 months vs. 12.7 months for crizotinib, with common side effects including cough, itching, and rash.

FDA approved ensartinib for ALK-positive advanced NSCLC, showing improved PFS vs crizotinib in phase 3 study. Ensartinib, manufactured by Xcovery and Betta, offers a new first-line treatment option with manageable AEs and potential cost-effectiveness.

EyePoint Pharmaceuticals granted 23,600 stock options to four new employees on Nov 15, 2024, as inducement awards outside the 2023 LTIP, per NASDAQ Rule 5635(c)(4). The options, priced at $9.17/share, have a 10-year term and vest over four years.